Biolexis Raises $10M in Series A Funding to Advance AI-Driven Drug Discovery for Multiple Diseases
Biolexis Therapeutics focuses on developing small molecules targeting a range of diseases including cancers, immune-mediated, neurodegenerative, autoimmune, metabolic, and inflammatory conditions
